AIMRNA, INC.

Biotech · Private

Bioengineered miRNA and siRNA therapeutic agents produced via tRNA/pre-miRNA hybrid carriers in E. coli, with natural posttranscriptional modifications to reduce immunogenicity.

Grants
$224K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Novel bioengineering platform to produce natural RNAi agents$224,158
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3191MABLOC, LLC——
3192Armo Biosciences——
3193ANCILIA, INC.——
3194AIMRNA, INC.——
3195VIOMEDIX, LLC——
3196BIOTRACKING LLC——
3197Nashville Clinic, LP—$800K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.